The Journal of Allergy and Clinical Immunology: In Practice
Volume 6, Issue 4, July–August 2018, Pages 1191-1197.e5
Original ArticlePredicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis
Under a Creative Commons license
open access
Key words
Chronic spontaneous urticaria
LASSO model
Urticaria activity score
Chronic urticaria
Symptom return
Omalizumab
Treatment discontinuation
Abbreviations used
AAC
Area above the curve
AUC
Area under the curve
BOCF
Baseline observation carried forward
CSU
Chronic spontaneous urticaria
CU
Chronic urticaria
LASSO
Least absolute shrinkage and selection operator
LOCF
Last observation carried forward
RCT
Randomized controlled trial
UAS
Urticaria activity score
UAS7
Urticaria activity score over 7 days
Cited by (0)
No funding was received for this work.
Conflicts of interest: M. Ferrer served in advisory boards for Genentech, and has received a research grant, advisory and speaker fees from Novartis. A. Giménez-Arnau was a Principal Investigator in the ASTERIA II and GLACIAL omalizumab studies, has served on advisory boards for Genentech, and has received a research grant, advisory and speaker fees from Novartis. D. Saldana, N. Janssens, M.-M. Balp, S. Khalil, and V. Risson are employees of Novartis.
© 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.